Form 8-K · Current Report · Filed 2024-02-08
Illumina Announces Q4 and FY 2023 Financial Results with Goodwill Impairment
Illumina, Inc. announced its financial results for the fourth quarter and fiscal year 2023, reporting a GAAP diluted loss per share of $(1.11) for Q4 2023 and $(7.34) for FY 2023. The company reported non-GAAP diluted earnings per share of $0.14 for both Q4 2023 and FY 2023. The company also reported a goodwill impairment of $827 million related to the GRAIL segment for FY 2023. Revenue for Q4 2023 was $1.12 billion, and for FY 2023, it was $4.50 billion. Illumina also announced the decision to divest GRAIL and has submitted a confidential draft registration statement to the SEC. Exhibits related to the financial results are furnished with the report.
- Filer
- Illumina, Inc. ILMN · NASDAQ
- Filed
- Accession
- 0001110803-24-000007
- CIK
- 0001110803
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$139.05
Next session
-3.6%
Since filing
+47.5%
Latest close
$205.10
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ILMN reporting the same item, with the next session's move:
Exhibits (1)
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Never miss another ILMN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.